Download PDFPDF

Ocular coloboma: a reassessment in the age of molecular neuroscience
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Authors' reply
    • Cheryl Y Gregory-Evans, Senior Lecturer
    • Other Contributors:
      • Matthew Williams, Stephanie Halford, and Kevin Gregory-Evans

    Dear Editors,

    We would like to thank Dr. Brooks and his colleagues for their interest in our article and their valuable remarks. As for the specific issues raised:

    We feel that this as a good time to redefine the use of terms associated with 'coloboma'. We would however suggest that this single word be used to encompass all entities rather than 'uveal coloboma' for two reasons. Firstly, 'uveal coloboma' is...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Caveats About Coloboma
    • Brian P Brooks, Staff clinician
    • Other Contributors:
      • National Institutes of Health

    Dear Editors

    We very much enjoyed reading the review article by Gregory-Evans et al. on coloboma in the December issue of the Journal of Medical Genetics. The authors should be commended on the most thorough treatment of the subject in the clinical genetics literature to date. In reading it, however, we thought there were a few additional points that required clarification.

    The first is the use of t...

    Show More
    Conflict of Interest:
    None declared.